Our Mission
Safety. Supply. Efficacy.
By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of adjuvanted subunit vaccines of global importance for the treatment and prevention of infectious diseases.
Brief History
Curevo Vaccine Origins
Collaboration
Research Collaboration between IDRI and MOGAM Institute for Biomedical Research (part of GC Pharma).
Curevo
Curevo Vaccine was created as the vehicle to develop and launch CRV-101 – Shingles Vaccine. We opened our first office in downtown Seattle with 2 employees - Emma Fritzen and Lisa Shelton.
Phase I
Phase I clinical trial started to analyze the safety and immunology data. George Simeon joins the company as a CEO and Julie Brooks as a General Counsel.
Phase I Completed
Phase I trial was completed with successful results. Four more team members join our team including Greg Curhan as a CFO, Anna Wrem as a Program Manager, and Shannan Moran as an Office Manager.
Immunology
Phase 1 trial immunology completed. Three more members join our team - Renae Koepke, Paul FitzMorris & Aaron Shoemaker. Preparations for Phase II and EMA EA Submission.
Series-A
On December 30th, we closed a $60M Series-A financing round led by RA Capital, Adjuvant Capital, Janus Henderson Investors, GC Pharma, and e&.
Phase 2b
Phase 2b clinical trial starts. Four new members join Curevo team - Megan Real-Hall, Sein Pyo, Andrea Wang and Svetlana Betz. We move to our new office in Bothell, WA.
